Please login to the form below

Not currently logged in
Email:
Password:

EC grants MSD’s Prevymis orphan product designation

The product will gain some market exclusivity benefits in CMV infection

MSDThe European Commission has granted Merck Sharp & Dohme’s new CMV prevention medication orphan medicinal product status, handing it a package of benefits that will include some market exclusivity.

The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

CMV infection is a common, clinically significant complication in patients taking an immunosuppressant medication as part of a HSCT regimen, which is a life-saving treatment for more than 70 different diseases including leukaemia, lymphoma and sickle cell anaemia.

The EC’s decision came on the back of phase III data showing that after 24 weeks following a transplant, only 37.5% of patients on letermovir developed a CMV infection compared to 60.6% patients on placebo.

The treatment - which MSD acquired from German biotech AiCuris - has already been approved for use in the same disease indication for the US last year.

Around the same time, Prevymis also gained a positive opinion from the Committee for Medicinal Products for Human Use, which gave the approval for the treatment to be used as both as an injectable and tablets.

Louise Houson, UK managing director of MSD, said: “MSD is delighted that the EC has recognised the potential of letermovir for prophylaxis of CMV reactivation in certain patients in need of a new option.”

According to the NHS, approximately 50-80% of adults in the UK are thought to have CMV, and once infected it can persevere in the body as an inactive or latent state.

However the first-in-class antiviral drug inhibits viral replication by specifically targeting the viral terminase complex.

Houson continued: “This authorisation brings us a step closer to making letermovir available in the UK and we will continue to work closely with NICE, NHS, SMC and other relevant stakeholders to help ensure that appropriate patients have access to letermovir as soon as possible.”

Article by
Gemma Jones

31st January 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics